Question follow-through · 91860
NHS: Drugs
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of how major pharmaceutical companies’ pricing strategies affect the VPAG’s ability to control NHS spending; and what steps are being taken to prevent higher
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 17 Nov 2025
- Target answer date
- 19 Nov 2025
- Answer
- 25 Nov 2025 · 8 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
17 Nov 2025
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of how major pharmaceutical companies’ pricing strategies affect the VPAG’s ability to control NHS spending; and what steps are being taken to prevent higher
19 Nov 2025
Target answer date
Date supplied by the official written-questions record.
25 Nov 2025
Answer published
The Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) controls the cost of sales of branded medicines to the National Health Service. The VPAG has a variable headline payment percentage, which accounts for changes to the cost of med...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.